Should you sell Abbott Laboratories or reduce the position?
Calculate what you would remove, what you would retain, and which assumptions support continuing to own it.
Price as of Oct 25, 2026, 7:45 PM UTC (polygon last daily bar) · Evidence through Oct 19, 2026
What has changed in the case for owning it?
Market Ontology's model values Abbott Laboratories at $64.21 per share against $103.70 (-38.1%). 8 dated developments in the last 45 days reach the position.
| Development | Evidence | Assumption affected | Consequence for the case |
|---|---|---|---|
| Oct 19, 2026 · Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli Lilly | 1 source | institutional defensives rebalancing | Supports the case for owning |
| Oct 13, 2026 · Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook | 2 sources | earnings revision momentum ahead of October 21 print | Supports the case for owning |
| Oct 13, 2026 · Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42 | 1 source | device volume and diagnostic sales revenue acceleration | Supports the case for owning |
| Oct 13, 2026 · Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS | 1 source | medical device and diagnostics volume expansion flowing to quarterly revenue | Supports the case for owning |
| Oct 13, 2026 · Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast | 1 source | operating earnings and revenue expansion into Q3 results | Supports the case for owning |
What changes if you sell?
| Keep current position | Sell selected quantity | Exit position | |
|---|---|---|---|
| Shares remaining | 100 | 50 | 0 |
| Estimated proceeds after included transaction costs | — | $5,182 | $10,365 |
| Downside case ($41.67) outcome | −$6,203 | −$3,102 | $0 |
| Upside case ($104.87) outcome | $117 | $59 | $0 |
| Remaining exposure | $10,370 | $5,185 | $0 |
Included costs: an assumed 5 bps for commission and spread. Tax treatment: not calculated; cost basis is not used in this comparison.
Undecided: sale proceeds and remaining exposure are calculated; replacement performance is left unresolved.
What would justify keeping the remaining position?
- Revenue growth (yr 1) holds near -7.81%: Trailing 4-year revenue CAGR of -7.8%, faded toward terminal growth over 5 years.
- Operating margin (steady-state) holds near 16.99%: Anchored to mean operating margin of 17.0% across the last 4 reported periods.
- Discount rate (WACC) holds near 5.96%: CAPM baseline: 4.96% risk-free + β-0.00 × 5.5% ERP = 4.94%.
What would justify investigating it again after an exit?
- Implied revenue growth (next yr → terminal) moves relative to 12.83%: Growth rate that reconciles the current share price to a 5y DCF holding margin, WACC and terminal g fixed.
- Implied steady-state FCF margin moves relative to 24.4%: FCF margin the market needs to justify the current price at modeled growth and WACC.
- The price falls below the downside value of $41.67.
Preserve the reasoning behind the sale.
Save the reduction you're considering, the evidence behind it, and your conditions for reviewing the remaining position. If you exit, keep the research and specify what would justify revisiting ABT.
Should I buy?Should I hold?Should I hedge?How to hedgeImpact ledger